5090792025-10-012025-12-315090792025-04-012025-12-315090792025-10-012025-12-31in-capmkt:OtherExpenses1Member5090792025-04-012025-12-31in-capmkt:OtherExpenses1Memberiso4217:INRxbrli:pureiso4217:INRxbrli:shares509079GUFICBIONOTLISTEDINE742B01025Gufic Biosciences LimitedMain BoardEquity2025-04-012026-03-312026-02-132026-02-09INRLakhsQuarterlyThird quarterSingle segmentThe Company's business activity falls within a single operating segment i.e. Pharmaceuticals2026-02-1318:30:002026-02-1320:00:00Not applicable2025-10-012025-12-31UnauditedConsolidated231409900079050002322004000992683000158224000-140690000400887000835600007692000057321800021448020001772020000177202000311000002186600052966000012423600000001242360000124236000000010028300011.241.24001.241.240001. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. <BR> <BR> 2. The above results for the quarter ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 13, 2026.The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2025. <BR> <BR> 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. <BR> <BR> 4. The equity shares and basic/diluted earnings per share for the comparative period (quarter and period ended December 31, 2023) has been presented in accordance with Ind AS - 33-Earning per share. <BR> <BR> 5. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.2025-04-012025-12-31UnauditedConsolidated69218690003831200069601810003012557000557764000-508006000113536100027174100023183900016829410006384197000575984000057598400090700000621180001528180000423166000000042316600004231660000-140000010028300014.224.22004.224.22000Other Expenses573218000Other Expenses1682941000